Immunosuppression following heart transplantation: prospects and challenges.

about

An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA Human leukocyte antigens and alloimmunization in heart transplantation: an open debate.

P2860

Q36302476-A11897D4-ABB9-471C-843E-591F28CF90DA Q38246225-238579D5-5D94-4BF0-8E1A-8026F3AABB75

P2860

Immunosuppression following heart transplantation: prospects and challenges.

Item

http://www.wikidata.org/entity/Q38184649

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Immunosuppression following heart transplantation: prospects and challenges.

@en

type

Item

label

Immunosuppression following heart transplantation: prospects and challenges.

@en

prefLabel

Immunosuppression following heart transplantation: prospects and challenges.

@en

P1476

Immunosuppression following heart transplantation: prospects and challenges

@en

P2093

David H Chang

http://www.w3.org/2001/XMLSchema#string

Michelle M Kittleson

http://www.w3.org/2001/XMLSchema#string

P2860

Palliative Care in the Treatment of Advanced Heart Failure

Drug Therapy in the Heart Transplant Recipient: Part I: Cardiac Rejection and Immunosuppressive Drugs

T cell activation

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery

Use of a continuous-flow device in patients awaiting heart transplantation

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus

Acute cellular rejection following human heart transplantation is associated with increased expression of vitronectin receptor (integrin alphavbeta3)

Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

P304

181-194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.13.163

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jon A Kobashigawa

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24491091

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

Immunosuppression following heart transplantation: prospects and challenges.

about

P2860

P2860

Immunosuppression following heart transplantation: prospects and challenges.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921